Braskem SA is engaged in the manufacture, sale, import and export of chemicals, petrochemicals and fuels, as well as the production, supply and sale of utilities such as steam, water, compressed air and industrial gases... Show more
Braskem S.A., the largest thermoplastic resin producer in the Americas, holds a leading position in Brazil's petrochemical market with significant market share in polyethylene (PE), polypropylene (PP), and polyvinyl chloride (PVC). Its integrated operations span basic petrochemicals like ethylene and propylene, supported by plants in Brazil, the U.S., Mexico, and Europe. Competitive advantages include scale, a diversified geographic footprint, and pioneering biopolymers leadership, where it produces the world's green polyethylene from sugarcane ethanol.
Medium-term positioning hinges on the Transformation Program, emphasizing asset optimization, gas feedstock expansion, and renewable migration. By reducing reliance on costlier naphtha (currently ~80% of mix) toward a 60/40 naphtha/gas-ethanol split by 2030, Braskem aims for first-quartile global cost positioning. U.S. operations benefit from low-cost ethane, while Mexican Braskem Idesa ventures add PE capacity. However, structural risks include high leverage (~7.9x net debt/EBITDA) and governance tied to shareholders Petrobras and Novonor, with potential shifts via IG4 improving oversight.
Braskem's trajectory could pivot on several near-term events. Q1 2026 earnings, slated for May 12, will test seasonal recovery amid analyst EPS estimates around -$0.43; focus will be on EBITDA guidance and liquidity preservation after 2025's $557M recurring EBITDA (down 49% YoY).
Rio de Janeiro complex expansion (R$4.2B investment for +220kt ethylene/PE by 2028) advances "Switch to Gas," locking long-term Petrobras ethane supply for cost/emissions cuts. PRESIQ tax incentives (2027-2031) bolster chemical competitiveness, while Alagoas remediation settlements (R$1.2B, mostly post-2030) free cash for transformation.
Analyst revisions reflect caution: Bank of America downgraded to Underperform ($2.80 PT) on liquidity/debt risks (e.g., $383M 2026 maturities), UBS to Neutral ($3.80), but Citigroup upgraded to Hold recently. Consensus "Reduce" with $3.87 average PT signals mixed sentiment, potentially shifting on spread recovery proof.
Petrochemicals grapple with prolonged downcycle from China overcapacity and weak spreads, pressuring Braskem's 59% Brazil cracker utilization in Q4 2025. Tailwinds include projected Q1 2026 spread expansion (up 50%) from Middle East disruptions and U.S. demand via infrastructure/resins.
Braskem's business model amplifies macro sensitivities: naphtha/oil price volatility (42% of costs), BRL depreciation inflating imports/debt service on $9.4B gross debt. Brazil's 1.7-2.2% GDP growth forecast for 2026, Selic cuts to ~12%, and fiscal reforms could ease pressures, but high rates curb construction/PVC demand. Geopolitics (e.g., Red Sea) aids spreads short-term; regulatory tailwinds like antidumping on U.S. PE protect local sales. Sustainability regulations favor Braskem's green portfolio amid circular economy shifts.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It leverages advanced machine learning algorithms to analyze historical price patterns, volume data, and technical indicators, spotting developing trends and potential breakouts or reversals. Users can explore predictions across thousands of tradable instruments, with searchable categories by sector, market cap, or timeframe, plus historical accuracy context and customizable alerts for real-time notifications. This neutral, data-driven approach empowers informed decision-making amid market volatility. Discover how it can enhance your trading strategy today.
2026 spotlights execution of Braskem's decarbonization roadmap, targeting 15% Scope 1/2 GHG cuts by 2030 via 70 initiatives (1.8M tCO2e annual reduction potential). Feedstock shift to gas/renewables promises margin sustainability, with REIQ-funded expansions and Vesta hydrogen cogeneration advancing low-carbon ops. Consensus forecasts ~8% revenue growth, 95% earnings rebound, reflecting cycle normalization.
Market expansion eyes biopolymers scaling and U.S./Mexico synergies, countering competitive threats from Asia. Debt refinancing ($100M interest mid-2026) and leverage reduction via $600M 2025 cash gen are pivotal. Analyst price targets ($2.80-$5.00) hinge on spreads, BRL stability; governance post-IG4/Petrobras dynamics could unlock value. Watch capital allocation discipline, regulatory evolution (PRESIQ), and tech transitions for inflection points in this cyclical sector.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
a manufacturer of petrochemicals and other related products
Industry ChemicalsMajorDiversified
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| ANVLX | 10.76 | 0.09 | +0.84% |
| American Century Non-US Intrs Val A | |||
| LFGOX | 44.80 | 0.24 | +0.54% |
| Lord Abbett Focused Growth F3 | |||
| VIIIX | 596.29 | 3.01 | +0.51% |
| Vanguard Institutional Index Instl Pl | |||
| PWJAX | 37.74 | -0.02 | -0.05% |
| PGIM Jennison International Opps A | |||
| FPHAX | 33.72 | -0.23 | -0.68% |
| Fidelity Select Pharmaceuticals Port | |||
A.I.dvisor indicates that over the last year, BAK has been loosely correlated with AVNT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if BAK jumps, then AVNT could also see price increases.
| Ticker / NAME | Correlation To BAK | 1D Price Change % |
|---|---|---|
| BAK | 100% | -4.18% |
| Chemicals: Major Diversified industry (18 stocks) | 40% Loosely correlated | +2.70% |
The 10-day moving average for BAK crossed bearishly below the 50-day moving average on June 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on May 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BAK as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for BAK turned negative on May 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
BAK moved below its 50-day moving average on June 03, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BAK entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BAK's RSI Indicator exited the oversold zone, of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 75 cases where BAK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BAK advanced for three days, in of 256 cases, the price rose further within the following month. The odds of a continued upward trend are .
BAK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BAK's P/B Ratio (142.857) is very high in comparison to the industry average of (9.344). BAK has a moderately low P/E Ratio (0.000) as compared to the industry average of (33.897). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (20.317). BAK has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (0.114) is also within normal values, averaging (1.968).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BAK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.